Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
The Readout Loud
00:00
Biotec Companies
Gilead has had so much success, like we said, but are now sort of struggling to kind of make this third act. And it is just interesting to me, tha, atwhen we don't see these companies kind of getting to a point where they can kind of become the next fizer, or the next roch or novardis, right? They just sort of, they struggle. But at the same time, they're still counted by people who are investing in the biote and pharma space as growthy biotec companies.
Transcript
Play full episode
